MarketLens

What is Latus Bio's "Gene Therapy 2.0" and Why Does it Matter

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What is EcoCharge Solutions, and Why Does it Matter Now

4 months ago

What is Upstart's Cash Line and Why Does it Matter

5 months ago

What is Google's Gemini Embedding 2 and Why Does It Matter

4 months ago

What is PanTracer Pro and Why Does it Matter for Cancer Diagnostics

5 months ago

Shape Therapeutics Receives Research Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance SHP-201, a One-Time Gene Therapy to Treat Parkinson’s Disease

Shape Therapeutics received a research grant from The Michael J. Fox Foundation to advance IND-enabling studies of SHP-201, its lead gene therapy candidate for Parkinson's disease.

Stock News•1 months ago

A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics

A new CRISPR molecule that destroys cells expressing specific signals could advance gene-editing medicines. The technology may expand CRISPR Therapeutics' toolkit if successfully developed.

DNA

Stock News•1 months ago

MeiraGTx: The Market Is Missing The Manufacturing Pivot

MeiraGTx is pivoting to a late-stage, manufacturing-enabled genetic medicine firm with near-term regulatory catalysts. A recent equity raise and milestone payments extend cash runway through 2H 2028, ...

MGTX

Stock News•1 months ago

Latus Bio Appoints Bethany Mancilla as Chief Business Officer

Latus Bio appointed Bethany Mancilla as Chief Business Officer, citing her corporate development experience in gene therapy and CNS disorders. The move comes as the company advances LTS-201 toward the...

CNS